Comparison of CollPlant Holdings Ltd. (CLGN) and Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)

This is therefore a comparing of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in CollPlant Holdings Ltd. (NASDAQ:CLGN) and Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CollPlant Holdings Ltd. 5.34M 3.75 3.77M 0.00 0.00
Eloxx Pharmaceuticals Inc. N/A 0.00 50.51M -1.42 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for CollPlant Holdings Ltd. and Eloxx Pharmaceuticals Inc.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both companies.

Net Margins Return on Equity Return on Assets
CollPlant Holdings Ltd. -70.60% 0% 0%
Eloxx Pharmaceuticals Inc. 0.00% -107.1% -88.5%

Insider & Institutional Ownership

Roughly 23.69% of CollPlant Holdings Ltd. shares are owned by institutional investors while 52.9% of Eloxx Pharmaceuticals Inc. are owned by institutional investors. Insiders owned roughly 19.13% of CollPlant Holdings Ltd.’s shares. Competitively, insiders own roughly 0.3% of Eloxx Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CollPlant Holdings Ltd. -0.97% -11.92% -14% -7.78% -42.05% 21.43%
Eloxx Pharmaceuticals Inc. 0.64% 7.57% -2.03% -34.98% -28.93% -7.74%

For the past year CollPlant Holdings Ltd. had bullish trend while Eloxx Pharmaceuticals Inc. had bearish trend.

Summary

CollPlant Holdings Ltd. beats Eloxx Pharmaceuticals Inc. on 7 of the 9 factors.

CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.